MedTrace Logo

Vienna Challenge Chamber Study Using RV658 in Subjects With Allergic Rhinitis

NCT01230619 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2010-12-06

No results posted yet for this study

Summary

RV568 is being developed for the treatment of diseases such as asthma, COPD and allergic rhinitis (e.g. hayfever). The main aim of this study is to investigate whether RV568 ameliorates the nasal symptoms to low doses of grass pollen in healthy subjects with seasonal allergic rhinitis.

Conditions

  • Seasonal Allergic Rhinitis

Interventions

DRUG

RV568

RV568 400 ug administered as nasal drops twice daily on Day 1, RV568 800 ug administered as nasal drops once daily on Day 2

DRUG

Placebo

Placebo administered as nasal drops twice daily on Day 1, Placebo administered as nasal drops once daily on Day 2

Sponsors & Collaborators

  • Respivert Ltd

    lead INDUSTRY

Principal Investigators

  • Prof Dr Friedrich Horak, MD · Institute for Allergy Research - Vienna Challenge Chamber

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2010-11-30
Completion
2010-12-31

Countries

  • Austria

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01230619 on ClinicalTrials.gov